Study Title
Phase I Trial of Brentuximab Vedotin for Refractory Chronic Graft-vs.-Host Disease (GVHD) (NCT01940796)

Trial Description
This research study is trying to determine the safest dose of brentuximab vedotin (also known as SGN-035) that can be given to patients with chronic Graft-vs.-Host Disease (GVHD) and see if chronic GVHD improves.

This trial is sponsored by Seattle Genetics/ Massachusetts General Hospital. [1]

Study data

  • Condition: Graft vs. Host Disease (GVHD)
  • Interventions:
  • Phase: I
  • Estimated Enrollment: 40
  • Start: October 2013
  • Estimated Completion: September 2019
  • Last verified: November 2014

Study Schematic

Screen Shot 2016-07-06 at 4.34.24 PM

Last Editorial review: July 6, 2016
Information based on (NIH/NCI) and other sources.